Date: 13th November, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.- Supply Agreement.
Ref: Scrip Code: 536565
Scrip Id: NOVELIX

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has entered into a supply agreement on 12th November, 2026 with M/s "axabio® NV" a Belgian biotechnology company specialising in the production of **natural astaxanthin** derived from microalgae (*Haematococcus pluvialis*).

Detailed information as required under Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, in respect of aforesaid appointment is given in 'Annexure I' to this letter.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you

Yours sincerely,

For Novelix Pharmaceuticals Limited

Gattu Gnana Prakash
Digitally signed by Gattu Gnana Prakash
Date: 2026.11.13 14:38:21 +05'30'

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

Annexure I

Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular Master No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No.	Disclosure Requirement	Details
1.	Name of Party with whom agreement/ Deed is signed	M/s. axabio® NV, Belgium
2.	Area of Agreement/Deed	Supply Agreement
3.	Domestic or International	International
4.	Share Exchange Ratio	Not Applicable
5.	Scope of Business Operation of Agreement/Deed	The Company has entered into a Supply Agreement with M/s. axabio® NV, Belgium, a biotechnology company specialising in the production of natural astaxanthin derived from microalgae (Haematococcus pluvialis), whereby M/s. axabio® NV shall be the supplier of natural astaxanthin to the Company in accordance with the terms and conditions mutually agreed between the parties.
6.	Details of consideration paid/ received in agreement /Deed	The Company expects meaningful revenue contribution from this agreement.
7.	Significant terms and conditions of agreement in brief	Under the Supply Agreement dated 12th November, 2026, the Company shall procure natural astaxanthin derived from microalgae (*Haematococcus pluvialis*) from M/s. axabio® NV, Belgium, in accordance with the specifications, quality requirements and commercial terms mutually agreed between the parties.
8.	Rationale and benefit expected.	The Company expects meaningful revenue contribution from this agreement.
9.	Any other disclosures related to such agreements	The agreement is entered into in the ordinary course of business and is expected to support the Company's business operations and strengthen its product portfolio in the field of astaxanthin-based products.
10.	Whether the agreement would fall within related party transactions? If yes, whether the same is done at arm's length	No. The agreement does not fall within the purview of related party transactions.

Gattu Gnana Prakash

Digitally signed by Gattu Gnana Prakash
Date: 2026.11.13 14:38:52 +05'30'